Stem Pharm, Inc

stempharm.com

Stem Pharm offers unique biomaterials for cell and tissue manufacturing. Applications include medical devices for drug discovery, cell therapy, and regenerative medicine. Stem Pharm's synthetic biomaterials support the optimization of cell expansion and differentiation, human tissue formation and cell/tissue delivery applications. Through control of the biomaterial properties (e.g. mechanical stiffness, cell adhesion, degradability), and utilizing chemistries that maintain cellular health and function, we provide cell-specific biomaterials to researchers and clinicians to fill unmet needs in their workflows. Currently, cell and tissue manufacturing processes often rely on animal-derived biomaterials that are complex and variable in nature and problematic for human in vivo applications due to potential pathogen transmission or an immunogenic response. Our materials are synthetic, defined, and optimized to produce functional cells and tissues and deliver them to areas of clinical need.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

ALLOY THERAPEUTICS ACQUIRES DEEPCDR BIOLOGICS TO BRING BIOINFORMATICS AND MACHINE LEARNING TO ITS ANTIBODY DISCOVERY OFFERING

Alloy Therapeutics | December 10, 2021

news image

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire ...

Read More

INDUSTRIAL IMPACT

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

news image

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More

MEDTECH

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

news image

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More
news image

MEDTECH

ALLOY THERAPEUTICS ACQUIRES DEEPCDR BIOLOGICS TO BRING BIOINFORMATICS AND MACHINE LEARNING TO ITS ANTIBODY DISCOVERY OFFERING

Alloy Therapeutics | December 10, 2021

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire ...

Read More
news image

INDUSTRIAL IMPACT

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More
news image

MEDICAL

GENETIC LEAP AND ASTELLAS ESTABLISH RESEARCH COLLABORATION TO DEVELOP RNA-TARGETED SMALL MOLECULES FOR ONCOLOGY TARGET

Genetic Leap | March 11, 2022

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...

Read More
news image

MEDTECH

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More